The GROWTH consortium, funded by the European Commission (2019-2023), is made up to train a new generation of researchers working on new pathological insights, biomarker diagnostics and personalized nutritional interventions for intestinal failure in neonates and preterm infants.
Academic and industry partners, covering various disciplines ranging from fundamental research to clinical paediatrics and analytical chemistry to organoid and gut-on-chip applications, have teamed up in the European Union.
GROWTH aims to set-up a new European platform that trains young scientists in the industry-led exploration of innovative routes to fully exploit the potential of early life nutrition to prevent inflammatory disease. GROWTH coordinates 8 individual research projects.
If you have any questions you can fill in the form or mail us directly: firstname.lastname@example.org.
It is becoming evident that modulation of gut microbes will be increasingly employed to promote overall health and to help treat disease, although optimal strategies for “precision” gut microbiota modulation remain incompletely understood. It is probable that a personalized approach will be needed, ncorporating strategies such as fecal microbiota transplant, administration of live biotherapeutics, dietary strategies, and prebiotics—although it is not inconceivable that an ideal “onesize- fits-all” approach could be identified. Through additional research and collaborative efforts, the true definition of dysbiosis in the gut microbiota as it relates to disease states can be better understood, as well as what constitutes an optimal gut microbiota to promote overall health, which could have broad impact for public health.
Reference: Wargo JA. Modulating gut microbes. Science. 2020; 369(6509):1302-3. doi: 10.1126/science.abc3965.
Wed, 21 October